Healthcare / BiotechnologyTaipei Exchange
$67.00
+0.40 (+0.60%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-107.4M · quality 68.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-11.3%
↓Gross Margin
78.7%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-47.7%
FCF CAGR
—
FCF margin
-206746.8%
FCF / Net income
0.79x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $47000.0 · net income $-123.7M · FCF $-97.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $47000.00 | $47000.00 | — | — | $328000.00 |
| Net Income | $-123.7M | $-123.7M | $-150.4M | $-170.9M | $-140.2M |
| EBITDA | $-103.8M | $-103.8M | $-119.6M | $-141.2M | $-117.1M |
| EPS | — | — | -2.11 | -2.43 | -2.02 |
| Gross Margin | 78.7% | 78.7% | — | — | 88.4% |
| Operating Margin | -298140.4% | -298140.4% | — | — | -45252.4% |
| Net Margin | -263287.2% | -263287.2% | — | — | -42737.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 |
| Current Ratio | 42.27 | 42.27 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-97.2M | $-97.2M | $-107.4M | $-125.5M | $-99.6M |
| Returns | |||||
| ROE | -11.3% | -11.3% | -12.6% | -12.9% | -9.6% |
| Valuation | |||||
| P/B | 4.38 | 4.38 | 2.84 | 3.54 | 4.97 |
| Growth & Yield | |||||
| EPS Growth | — | — | 13.2% | -20.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+24.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.11 → n/d
Residual
+24.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.